---
subject: Monthly Newsletter Vol.157 - September 2017
---

{{> header-secondary }}

<wrapper class="header header-primary">
	<container>
		<row class="collapse">
			<columns small="12" large="6" valign="middle">
				<img class="logo logo-ddc small-float-center" src="https://blog.drugs.com/wp-content/uploads/2018/02/logo-ddc.jpg" width="211" height="44" alt="Drugs.com">
			</columns>
			<columns small="12" large="6">
				<p class="small-text-center text-right" valign="middle">
					<span class="header-title">Monthly News Roundup</span><br>
					<span class="header-sub-title">Vol 157, September 2017</span>
				</p>
			</columns>
		</row>
	</container>
</wrapper>

<container>
	
	<row>
		<columns small="12">
			<h2>Featured News</h2>
			<p>Lilly's new targeted breast cancer agent, Verzenio, clears the FDA this month, as does GSK's Trelegy Ellipta, a triple drug, once daily inhaler for COPD. Solosec, a single-dose oral treatment for bacterial vaginosis expands new antibiotic options, and Bayer's Aliqopa for relapsed follicular lymphoma joins the booming oncology market. Plus, Amgen's Mvasi is the seventh approved U.S. biosimilar and the first for any cancer indication.</p>
			<center>
				<button href="#" class="radius btn-offset">Read More</button>
			</center>
		</columns>
	</row>

	<row>
		<columns small="12">
			<hr>
			<h2>New Drug Approvals</h2>
			<p>The following drugs have recently been approved by the FDA.</p>
			<ul class="list-featured list-unstyled">
				<li>
					<a href="#">Verzenio</a> (abemaciclib) Tablets
					<p><strong>Date of Approval:</strong> September 28, 2017<br>
					<strong>Treatment for:</strong> Breast Cancer<br>
					 <a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Ocrevus</a> (ocrelizumab) Injection
					<p><strong>Date of Approval:</strong> September 18, 2017<br>
					<strong>Treatment for:</strong> Chronic Obstructive Pulmonary Disease<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Xhance</a> (fluticasone propionate) Nasal Spray
					<p><strong>Date of Approval:</strong> September 18, 2017<br>
					<strong>Treatment for:</strong> Nasal Polyps<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Adzenys ER</a> (amphetamine) Extended-Release Liquid Suspension
					<p><strong>Date of Approval:</strong> September 15, 2017<br>
					<strong>Treatment for:</strong> Attention-Deficit Hyperactivity Disorder (ADHD)<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Solosec</a> (secnidazole) Oral Granules
					<p><strong>Date of Approval:</strong> September 15, 2017<br>
					<strong>Treatment for:</strong> Bacterial Vaginosis<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Mvasi</a> (bevacizumab-awwb) Injection
					<p><strong>Date of Approval:</strong> September 14, 2017<br>
					<strong>Treatment for:</strong> Non-Small Cell Lung Cancer, Colorectal Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Aliqopa</a> (copanlisib) Injection
					<p><strong>Date of Approval:</strong> September 14, 2017<br>
					<strong>Treatment for:</strong> Follicular Lymphoma<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Mylotarg</a> (gemtuzumab ozogamicin) Injection
					<p><strong>Date of Approval:</strong> September 1, 2017<br>
					<strong>Treatment for:</strong> Acute Myeloid Leukemia<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
			</ul>
			<center>
				<button href="#" class="radius btn-offset">More Drug Approvals</button>
			</center>
		</columns>
	</row>

{{> sponsored }}

	<row>
		<columns small="12">
			<h2>New Indications and Dosage Forms</h2>
			<p>Drugs that have gained FDA approval for the treatment of additional diseases/conditions or new dosage forms/regimens.</p>
			<ul class="list-featured list-unstyled">
				<li>
					<a href="#">Tracleer</a> (bosentan) Film-Coated Tablets and Tablets for Oral Suspension
					<p><strong>New Dosage Form Approved:</strong> September 5, 2017<br>
					<strong>Now Approved:</strong> Dispersible Tablets for Pediatric Patients with Pulmonary Arterial Hypertension<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Briviact</a> (brivaracetam) Tablets, Solution and Injection
					<p><strong>New Indication Approved:</strong> September 14, 2017<br>
					<strong>Now Approved:</strong> Monotherapy for Partial-Onset Seizures<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Opdivo</a> (nivolumab) Injection
					<p><strong>New Indication Approved:</strong> September 22, 2017<br>
					<strong>Now Approved for:</strong> Hepatocellular Carcinoma Patients Previously Treated with Sorafenib<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Keytruda</a> (pembrolizumab) for Injection
					<p><strong>New Indication Approved:</strong> September 22, 2017<br>
					<strong>Now Approved for:</strong> Metastatic Gastric or Gastroesophageal Junction Cancer<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Somatuline Depot</a> (lanreotide acetate) Injection
					<p><strong>New Indication Approved:</strong> September 15, 2017<br>
					Now Approved for:</strong> Carcinoid Syndrome<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Privigen</a> (immune globulin intravenous (human)) Liquid
					<p><strong>New Indication Approved:</strong> September 14, 2017<br>
					<strong>Now Approved for:</strong> Chronic Inflammatory Demyelinating Polyneuropathy<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Rapivab</a> (peramivir) Injection
					<p><strong>Patient Population Altered:</strong> September 20, 2017<br>
					<strong>Now Approved for:</strong> Influenza in Pediatric Patients 2 Years and Older<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
				<li>
					<a href="#">Aptiom</a> (eslicarbazepine acetate) Tablets
					<p><strong>Patient Population Altered:</strong> September 13, 2017<br>
					<strong>Now Approved for:</strong> Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older<br>
					<a href="#">Release</a> | <a href="#">Approval History</a></p>
				</li>
			</ul>
			<center>
				<button href="#" class="radius btn-offset">Read More</button>
			</center>
		</columns>
	</row>

	<row>
		<columns small="12">
			<hr>
			<h2>First-Time Generic Approvals</h2>
			<p>First Time Generics are those drug products that have never been approved before as generic drug products and are new generic products to the marketplace.</p>
			<ul class="list-featured list-unstyled">
				<li>
					<a href="#">Oseltamivir Phosphate for Oral Suspension</a>
					<p><strong>6 mg (base)/mL</strong><br>
					Approved: September 14, 2017 - Nesher Pharmaceuticals (USA) LLC<br>
					Generic for: <strong>Tamiflu for Oral Suspension</strong></p>
				</li>
			</ul>
			<center>
				<button href="#" class="radius btn-offset">Read Approvals</button>
			</center>
		</columns>
	</row>

	<row>
		<columns small="12">
			<hr>
			<h2>Other Drug News</h2>
			<ul>
				<li><a href="#">Whooping Cough Shot Works, But Many Moms-to-Be Skip It: CDC</a></li>
				<li><a href="#">It's Time to Get Your Flu Shot Again</a></li>
				<li><a href="#">FDA Approves New Continuous Glucose Monitor for Diabetes</a></li>
				<li><a href="#">Many Patients Denied Costly New Cholesterol Drugs</a></li>
				<li><a href="#">Adding Rituximab to Standard Care May Prolong Lymphoma Survival</a></li>
				<li><a href="#">Many With Work-Related Asthma Not Getting Key Vaccine</a></li>
			</ul>
			<center>
				<button href="#" class="radius btn-offset">More New Updates</button>
			</center>
		</columns>
	</row>

	<row class="row-trim-columns">
		<columns small="12">
			<hr>
			<img class="logo-fda" src="https://media.drugs.com/wp-content/uploads/2018/01/logo-fda.jpg" alt="U S Food and Drug Administration" width="230" height="50">
			<spacer size="18"></spacer>
		</columns>
	</row>
	<row>
		<columns small="12">
			<p class="header-label text-uppercase">FDA MedWatch Alerts</p>
			<ul>
				<li><a href="#">Vegetable Vigra by Natures Supplement: Recall - Undeclared Drug Ingredient</a></li>
				<li><a href="#">Drug Safety Communication: Ocaliva (obeticholic acid) - Increased Risk of Serious Liver Injury</a></li>
				<li><a href="#">Recall: Rhino 7, Papa Zen, Fifty Shades, and Grande X Dietary Supplements by Gadget Island - Undeclared Drug Ingredients</a></li>
				<li><a href="#">Drug Safety Communication: Opioid Addiction Medications in Patients Taking Benzodiazepines or CNS Depressants - Careful Medication Management Can Reduce Risks</a></li>
				<li><a href="#">Recall: Activase (alteplase) 100mg by Genentech - Lack of Sterility Assurance</a></li>
				<li><a href="#">Drug Safety Communication: Kayexalate (sodium polystyrene sulfonate) - FDA Recommends Separating Dosing</a></li>
				<li><a href="#">Recall: Hydromorphone HCl Injection, USP 2 mg/mL, and Levophed (Norepinephrine Bitartrate Injection, USP) 4 mg/4 mL (1 mg/mL) Vial by Hospira: - Lack of Sterility Assurance</a></li>
				<li><a href="#">Alcohol Pads or Benzalkonium Chloride Antiseptic Towelettes by Foshan Flying Medical Products: FDA Alert - Lack of Sterility Assurance and Other Quality Issues</a></li>
				<li><a href="#">Recall: Unexpired Lots of Oxytocin Compounded with Either Lactated Ringers or Lactated Ringers and Dextrose by PharMEDium - Sub-Potency</a></li>
			</ul>
			<center>
				<button href="#" class="radius btn-offset">More FDA MedWatch Alerts</button>
			</center>
		</columns>
	</row>
	<row>
		<columns small="12">
			<spacer size="20"></spacer>
			<p class="header-label text-uppercase">FDA Consumer Updates</p>
			<ul>
				<li><a href="#">Depression: FDA-Approved Medications May Help</a></li>
				<li><a href="#">Dealing with ADHD: What You Need to Know</a></li>
				<li><a href="#">Making Decisions for Your Health: Getting the Info You Need</a></li>
				<li><a href="#">FDA: Cutting-Edge Technology Sheds Light on Antibiotic Resistance</a></li>
			</ul>
			<center>
				<button href="#" class="radius btn-offset">More FDA Updates</button>
			</center>
		</columns>
	</row>

	<row class="row-trim-columns">
		<columns small="12">
			<hr>
			<h2>Tools &amp; Helpful Links</h2>
			<spacer size="12"></spacer>
		</columns>
	</row>
	<row class="row-trim-columns list-resources">
		<columns small="12" large="6">
			<ul class="list-secondary list-unstyled">
				<li><a href="#">Interactions Checker</a></li>
				<li><a href="#">Compare Drugs</a></li>
				<li><a href="#">News &amp; Alerts</a></li>
			</ul>
		</columns>
		<columns small="12" large="6">
			<ul class="list-secondary list-unstyled">
				<li><a href="#">Pill Identifier</a></li>
				<li><a href="#">Medical Q &amp; A</a></li>
				<li><a href="#">My Med List</a></li>
			</ul>
		</columns>
	</row>

	<row>
		<columns small="12">
			<p class="text-secondary text-medium text-muted">This information is not intended to be medical advice. You should contact your physician before making any changes to your health care. Drugs.com is not responsible for content provided by third-party websites.</p>
			<p class="text-secondary text-medium text-muted">The Editorial Team,<br>Drugs.com</p>
		</columns>
	</row>

</container>

{{> footer }}